Minerva Surgical's Preliminary FY21 Revenues Top Expectations


Medical device company Minerva Surgical Inc UTRS expects Q4 FY21 sales of $13.5 million - $13.7 million, versus $13.6 million posted a year ago and the consensus of $13.45 million.

  • FY21 sales are expected to be $52.0 million - $52.2 million (prior view $51.0 million - $52.0 million), compared to $37.8 million in FY20 and the consensus of $51.75 million.
  • Ended 2021 with over $40 million in cash and cash equivalents, reflecting the proceeds from the company's initial public offering completed on October 26, 2021.
  • Refinanced existing debt with a new $40 million, five-year term loan from CIBC, substantially reducing the company's overall cost of capital.
  • "We are also setting the foundation for our "direct to consumer/patient" marketing effort, while at the same time, onboarding a significant number of new sales territory managers. Overall, we feel optimistic about our revenue growth in the coming year despite the macro-environment that the Omicron variant and hospital staffing shortages are continuing to impose on elective surgeries," said CEO David Clapper.
  • Price Action: UTRS shares closed 4.66% higher at $5.62 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!